Sign In
Buy VBLT
$0.156
+0 (+0%)
At Close: Jan 12, 2024
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript
01:45pm, Wednesday, 23'rd Mar 2022
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
01:25pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates
10:32am, Wednesday, 23'rd Mar 2022
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
01:57pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for d
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
12:00pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for d
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
09:57am, Monday, 14'th Mar 2022
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
08:00am, Monday, 14'th Mar 2022
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for dif
VBL Therapeutics to Participate at March Investor Conferences
08:00am, Thursday, 03'rd Mar 2022
TEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-t
Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates
10:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09:05pm, Tuesday, 15'th Feb 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-
Vascular Biogenics (VBLT) Investor Presentation - Slideshow
08:03pm, Monday, 14'th Feb 2022 Seeking AlphaVBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
08:00am, Wednesday, 02'nd Feb 2022
TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-tr
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
01:10pm, Thursday, 06'th Jan 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
08:10am, Thursday, 06'th Jan 2022
TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat m
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
12:30pm, Monday, 20'th Dec 2021 GlobeNewswire Inc.
VBL is among only 9% of companies across industries selected by the EIC Accelerator
